ST Pharm recently celebrated the completion of its groundbreaking ceremony, marking a significant stride in its efforts to expand its oligonucleotide manufacturing capacity and capabilities.

Following FDA authorization and CDC recommendation, Rite Aid (NYSE: RAD) has announced that eligible customers can now schedule appointments to receive the updated COVID-19 (2023-2024) vaccines at its locations and Bartell Drugs locations in the Pacific Northwest. Appointments are available starting on Friday, September 22.

Daiichi Sankyo (TSE: 4568) has announced that quizartinib has received a favorable recommendation for approval in the European Union (EU). This approval is for its use in combination with standard cytarabine and anthracycline induction, as well as standard cytarabine consolidation chemotherapy.

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF), a North American biopharmaceutical company dedicated to the development of patient-centric medications for orphan and rare diseases, has announced a significant update.

Acticor Biotech (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for treating cardiovascular emergencies, has announced its refined development plan for Acute Ischemic Stroke (AIS) aimed at obtaining glenzocimab's registration in Europe and the United States.

Biosyngen Pte Ltd (referred to as "Biosyngen") has announced that the U.S. FDA has granted clearance for the Investigational New Drug (IND) application for the Phase I/II clinical trial of BRL03.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company dedicated to discovering and developing targeted therapeutics, has initiated a Phase 1 monotherapy expansion in its first-in-human clinical trial assessing IDE161 (NCT 05787587).

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company specializing in novel antibody therapeutics, has entered into a significant agreement with Myricx Bio, a British biotechnology company focused on creating a new class of cytotoxic payloads specifically designed for antibody-drug conjugates (ADCs).

Mabwell (Stock Code: 688062.SH) is an innovative biopharmaceutical company with a comprehensive presence in the pharmaceutical industry value chain. The company is dedicated to providing more effective and accessible therapies and innovative medicines to meet global medical needs.

Verily, a subsidiary of Alphabet specializing in precision health technology, and Kyverna Therapeutics, a clinical-stage cell therapy company focused on developing therapies for autoimmune diseases, have announced a multi-year collaboration aimed at identifying novel biomarkers and innovating clinical trial design and execution.